The positive interim Phase I data evaluating a new oral formulation of SMT C1100 for Duchenne Muscular Dystrophy (DMD) is extremely encouraging and supports the potential development of an improved formulation. Full data from the Phase I trial is expected in due course. SMT C1100, the group’s lead utrophin modulator programme for DMD, received approval to initiate a Phase II proof of concept clinical trial, PhaseOut DMD, in January and we expect data from the first group of patients from H2 2016 onwards. There is currently no cure for DMD, a fatal muscle wasting Orphan disease in the US and Europe, which affects 1 in 3,500 males births, and unlike other approaches in development Summit’s utrophin modulation programmes are a potential disease modifying approach that could potentially be used by 100% of boys with DMD and in combination with other agents. We look forward to data from the Phase I trial with the new formulation and the PhaseOut trial later this year.
